Wykoff, Charles C <br/><br/>
Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.  [electronic resource] 

 -  Ophthalmology  Sep 2013 
 - 1945-6.e1 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-4713 
<br/><br/><label>Standard No.: </label>10.1016/j.ophtha.2013.06.030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Drug Resistance<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Ranibizumab<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis